BR112017016819A2 - compostos de diaza-benzofluorantreno - Google Patents

compostos de diaza-benzofluorantreno

Info

Publication number
BR112017016819A2
BR112017016819A2 BR112017016819-7A BR112017016819A BR112017016819A2 BR 112017016819 A2 BR112017016819 A2 BR 112017016819A2 BR 112017016819 A BR112017016819 A BR 112017016819A BR 112017016819 A2 BR112017016819 A2 BR 112017016819A2
Authority
BR
Brazil
Prior art keywords
diaza
fluoranthene compound
benzo
benzo fluoranthene
compound
Prior art date
Application number
BR112017016819-7A
Other languages
English (en)
Chinese (zh)
Other versions
BR112017016819B1 (pt
Inventor
Yuan Shujie
Yang Xinchun
Zhao Jinlong
Zhang Daoxu
Sun Mingda
Liu Jiaji
Wei Tao
Zhao Huanan
Luo Yunfu
Yang Chundao
Original Assignee
Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510058257.7A external-priority patent/CN105985333A/zh
Application filed by Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory filed Critical Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory
Publication of BR112017016819A2 publication Critical patent/BR112017016819A2/pt
Publication of BR112017016819B1 publication Critical patent/BR112017016819B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

descreve-se uma série de compostos de diaza-benzofluorantreno. a presente invenção refere-se com particularidade a um composto representado pela fórmula (i), seus sais ou tautômeros farmaceuticamente aceitáveis
BR112017016819-7A 2015-02-04 2016-02-02 Compostos de diaza-benzofluorantreno BR112017016819B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510058257.7A CN105985333A (zh) 2015-02-04 2015-02-04 二氮杂-苯并荧蒽类化合物
CN201510058257.7 2015-02-04
CN201610052158.2 2016-01-26
CN201610052158 2016-01-26
PCT/CN2016/073143 WO2016124129A1 (zh) 2015-02-04 2016-02-02 二氮杂-苯并荧蒽类化合物

Publications (2)

Publication Number Publication Date
BR112017016819A2 true BR112017016819A2 (pt) 2018-04-03
BR112017016819B1 BR112017016819B1 (pt) 2022-12-13

Family

ID=56563466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016819-7A BR112017016819B1 (pt) 2015-02-04 2016-02-02 Compostos de diaza-benzofluorantreno

Country Status (15)

Country Link
US (1) US10017507B2 (pt)
EP (1) EP3255044B1 (pt)
JP (1) JP6434170B2 (pt)
KR (1) KR101998011B1 (pt)
CN (1) CN107614498B (pt)
AU (1) AU2016214802B2 (pt)
BR (1) BR112017016819B1 (pt)
ES (1) ES2802526T3 (pt)
IL (1) IL253813B (pt)
PH (1) PH12017501404A1 (pt)
RU (1) RU2697513C9 (pt)
TW (1) TWI706950B (pt)
UA (1) UA121882C2 (pt)
WO (1) WO2016124129A1 (pt)
ZA (1) ZA201706005B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697513C9 (ru) * 2015-02-04 2019-12-19 Харбин Фармасьютикал Груп Ко., Лтд. Дженерал Фармасьютикал Фэктори Диазабензофторантреновые соединения
WO2018024225A1 (zh) * 2016-08-04 2018-02-08 哈药集团技术中心 二氮杂-苯并荧蒽类化合物的盐型和晶型
CN114920743B (zh) * 2022-05-09 2023-08-04 南京中医药大学 一种吲哚生物碱及其制备方法与应用
CN114939190B (zh) * 2022-06-14 2024-01-12 健诺维(成都)生物科技有限公司 一种用于青光眼治疗的引流管材料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142026B (it) * 1981-07-21 1986-10-08 Ausonia Farma Srl Nuovo composto ad attivita' eumetabolica cerebrale
HU191694B (en) * 1984-07-11 1987-03-30 Richter Gedeon Vegyeszet Process for production of new derivatives of amineburnan carbonic acid
JPH02152979A (ja) * 1988-12-06 1990-06-12 Taisho Pharmaceut Co Ltd アポビンカミン酸誘導体
CA2036337C (fr) * 1990-02-15 2003-04-15 Francois Clemence Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
JPH0867681A (ja) * 1994-06-24 1996-03-12 Hiroyoshi Hidaka アポビンカミン酸誘導体及びこれを含有する医薬
CN100500146C (zh) * 2003-10-28 2009-06-17 墨西哥国立自治大学 长春西汀及其衍生物在癫痫及其并发症的治疗和预防中的应用
RU2525433C2 (ru) * 2011-10-05 2014-08-10 Общество С Ограниченной Ответственностью "Фарма Старт" Лекарственный препарат винкамина в форме матричных таблеток для улучшения мозгового кровообращения и способ его изготовления
HU230482B1 (hu) * 2011-11-22 2016-07-28 Richter Gedeon Nyrt. Egy új diaza-benzofluorantén analóg gyógyszer
WO2013138101A2 (en) * 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
US9701676B2 (en) * 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
RU2697513C9 (ru) * 2015-02-04 2019-12-19 Харбин Фармасьютикал Груп Ко., Лтд. Дженерал Фармасьютикал Фэктори Диазабензофторантреновые соединения

Also Published As

Publication number Publication date
PH12017501404A1 (en) 2018-01-15
ES2802526T3 (es) 2021-01-20
ZA201706005B (en) 2020-01-29
TW201639836A (zh) 2016-11-16
IL253813A0 (en) 2017-09-28
RU2017130595A (ru) 2019-03-04
EP3255044A4 (en) 2018-01-17
KR101998011B1 (ko) 2019-07-08
KR20170109671A (ko) 2017-09-29
WO2016124129A1 (zh) 2016-08-11
RU2697513C9 (ru) 2019-12-19
IL253813B (en) 2020-08-31
AU2016214802B2 (en) 2018-08-30
US20180016270A1 (en) 2018-01-18
US10017507B2 (en) 2018-07-10
CN107614498B (zh) 2020-06-05
RU2697513C2 (ru) 2019-08-15
BR112017016819B1 (pt) 2022-12-13
TWI706950B (zh) 2020-10-11
UA121882C2 (uk) 2020-08-10
JP2018506582A (ja) 2018-03-08
CN107614498A (zh) 2018-01-19
EP3255044A1 (en) 2017-12-13
EP3255044B1 (en) 2020-04-01
RU2017130595A3 (pt) 2019-03-04
AU2016214802A1 (en) 2017-09-14
JP6434170B2 (ja) 2018-12-05

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
TW201613911A (en) Heterocyclic compounds and uses thereof
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
EA201990833A1 (ru) Соединение пиридина
MA39749A (fr) Dérivés de pipéridine-dione
EA201691534A1 (ru) Лечение устойчивых угрей
MY197698A (en) Oxysterols and methods of use thereof
MX2017013798A (es) Inhibidores jak.
BR112016029825A2 (pt) composto
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
PH12018500903A1 (en) Pyranodipyridine compound
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
JOP20200030A1 (ar) مركب خماسي الحلقة
DOP2018000042A (es) Antagonistas del receptor de cgrp
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
MX2018001517A (es) Derivados sustituidos de guanidina.
BR112017016819A2 (pt) compostos de diaza-benzofluorantreno
MY193239A (en) Novel b-lactamase inhibitors
EA201892449A1 (ru) Конденсированные гетероциклические соединения
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2016, OBSERVADAS AS CONDICOES LEGAIS